These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 32130964)

  • 1. The Therapeutic Landscape of Renal Cell Carcinoma: From the Dark Age to the Golden Age.
    Huang JJ; Hsieh JJ
    Semin Nephrol; 2020 Jan; 40(1):28-41. PubMed ID: 32130964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma.
    Chehrazi-Raffle A; Meza L; Alcantara M; Dizman N; Bergerot P; Salgia N; Hsu J; Ruel N; Salgia S; Malhotra J; Karczewska E; Kortylewski M; Pal S
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33688021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modern Systemic Therapy for Metastatic Renal Cell Carcinoma of the Clear Cell Type.
    Parikh M; Lara PN
    Annu Rev Med; 2018 Jan; 69():209-221. PubMed ID: 29144835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.
    de Velasco G; Bex A; Albiges L; Powles T; Rini BI; Motzer RJ; Heng DYC; Escudier B
    Eur Urol Oncol; 2019 Sep; 2(5):505-514. PubMed ID: 31377308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarker-Oriented Therapy in Bladder and Renal Cancer.
    Scholtes MP; Alberts AR; Iflé IG; Verhagen PCMS; van der Veldt AAM; Zuiverloon TCM
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete response to immune checkpoint inhibitors-based therapy in advanced renal cell carcinoma patients. A meta-analysis of randomized clinical trials.
    Iacovelli R; Ciccarese C; Schutz FA; Tortora G; de Velasco G
    Urol Oncol; 2020 Oct; 38(10):798.e17-798.e24. PubMed ID: 32773231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of tumor microenvironment in acquiring resistance to vascular endothelial growth factor-tyrosine kinase inhibitor and recent advance of systemic treatment of clear cell renal cell carcinoma.
    Mikami S; Mizuno R; Kosaka T; Tanaka N; Kuroda N; Nagashima Y; Okada Y; Oya M
    Pathol Int; 2020 Oct; 70(10):712-723. PubMed ID: 32652869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma.
    Lalani AA; Xie W; Braun DA; Kaymakcalan M; Bossé D; Steinharter JA; Martini DJ; Simantov R; Lin X; Wei XX; McGregor BA; McKay RR; Harshman LC; Choueiri TK
    Eur Urol Oncol; 2020 Jun; 3(3):372-381. PubMed ID: 31562048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New therapeutic approaches in the management of metastatic renal cell carcinoma.
    Gkialas IK; Papadopoulos G
    J BUON; 2009; 14(3):399-404. PubMed ID: 19810129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolving role of novel targeted agents in renal cell carcinoma.
    Hutson TE; Figlin RA
    Oncology (Williston Park); 2007 Sep; 21(10):1175-80; discussion 1184, 1187, 1190. PubMed ID: 17926797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management : Optimal Management for Renal Cell Cancer Patients.
    Cetin B; Wabl CA; Gumusay O
    Curr Treat Options Oncol; 2022 Apr; 23(4):609-629. PubMed ID: 35316480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
    McGregor BA; Lalani AA; Xie W; Steinharter JA; E Bakouny Z; Martini DJ; Fleischer JH; Abou-Alaiwi S; Nassar A; Nuzzo PV; Kaymakcalan MD; Braun DA; Wei XX; Harshman LC; Bilen MA; Choueiri TK
    Eur J Cancer; 2020 Aug; 135():203-210. PubMed ID: 32599410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective.
    Lavacchi D; Pellegrini E; Palmieri VE; Doni L; Mela MM; Di Maida F; Amedei A; Pillozzi S; Carini M; Antonuzzo L
    Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32630154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
    Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
    Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Signaling inhibitors in metastatic renal cell carcinoma.
    Escudier B
    Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Avelumab and axitinib combination therapy for the treatment of advanced renal cell carcinoma.
    Soleimani M; Nappi L; Kollmannsberger C
    Future Oncol; 2020 Dec; 16(36):3021-3034. PubMed ID: 32856478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
    Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine kinase and immune checkpoints inhibitors in favorable risk metastatic renal cell carcinoma: Trick or treat?
    Catalano M; Procopio G; Sepe P; Santoni M; Sessa F; Villari D; Nesi G; Roviello G
    Pharmacol Ther; 2023 Sep; 249():108499. PubMed ID: 37479037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders.
    Boilève A; Carlo MI; Barthélémy P; Oudard S; Borchiellini D; Voss MH; George S; Chevreau C; Landman-Parker J; Tabone MD; Chism DD; Amin A; Bilen MA; Bosse D; Coulomb-L'hermine A; Su X; Choueiri TK; Tannir NM; Malouf GG
    J Immunother Cancer; 2018 Dec; 6(1):159. PubMed ID: 30591082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibition for the treatment of renal cell carcinoma.
    Stühler V; Maas JM; Rausch S; Stenzl A; Bedke J
    Expert Opin Biol Ther; 2020 Jan; 20(1):83-94. PubMed ID: 31587590
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 27.